The Roche Group reported a 1% growth in sales to CHF 63.3 billion ($69.4 billion) in 2022 as revenue from new products overtook the impact of biosimilar competition and a drop in demand for Covid-19 products. At constant exchange rates, the increase was 2%. In a call with investors on 2 February, Severin Schwan, the outgoing chief executive, said the company had achieved good results, despite considerable headwinds. Sales are expected to decline this year due to a sharp decline in Covid-19 product revenue of about CHF 5 billion.
